首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1550638

PARP 抑制劑市場：按藥物類型、按應用、按分銷管道、按地區

PARP Inhibitor Market, By Drug Type, By Application, By Distribution Channel, By Geography

出版日期: 2024年07月26日 | 出版商:

Coherent Market Insights | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球PARP抑制劑市場規模為72億美元，預計2031年將達130.2億美元，2024年至2031年複合年成長率為8.8%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	72億美元
實際資料	2019-2023	預測期	2024年至2031年
預測 2024-2031 年複合年成長率：	8.80%	2031年價值預測	130.2億美元

圖. PARP抑制劑按地區市場佔有率（%），2024年

聚（ADP-核糖）聚合酵素（PARP）抑制劑是一種主要用於治療癌症的標靶治療。 PARP 抑制劑可透過阻斷 PARP 酶（修復受損 DNA）來幫助化療和放射線治療更有效地殺死癌細胞。全球 PARP 抑制劑市場的成長是由癌症發病率上升、PARP 抑制劑在癌症治療中的核准和採用增加所推動的。市面上主要的藥物包括奧拉帕尼、尼拉帕尼和魯卡帕尼，這些藥物在治療乳腺癌、卵巢和前列腺癌方面已被證明有效。隨著評估 PARP 抑制劑在新癌症類型和聯合治療中的潛力的研究正在進行，該市場可能會成長。

市場動態：

全球PARP抑制劑市場成長的驅動力是全球癌症發生率的增加以及PARP抑制劑在腫瘤學領域的核准和採用的擴大。根據世界衛生組織統計，2018年，癌症患者人數增加至1,810萬人，死亡人數增加至960萬人。正在進行的臨床試驗評估 PARP 抑制劑在更廣泛的患者群體中的療效以及與其他抗癌治療相結合，可能會推動市場成長。然而，PARP抑制劑的高價格、患者選擇時需要進行基因預篩檢以及藥物核准實施嚴格的監管途徑可能會阻礙市場成長。正在進行的探索新應用和新管道藥物的研究可能會在不久的將來為市場成長提供新的機會。

本研究的主要特點

該報告對全球 PARP 抑制劑市場進行了詳細分析，並提供了以 2023 年為基準年的預測期（2024-2031 年）的市場規模（十億美元）和年複合成長率（CAGR%）。它。
它還揭示了各個細分市場的潛在商機，並解釋了該市場中有吸引力的投資提案的矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
它包括基於公司亮點、產品系列、主要亮點、財務業績和策略等參數的全球 PARP 抑制劑市場主要企業的概況。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球 PARP 抑制劑市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球 PARP 抑制劑市場的各種策略矩陣來促進決策。

公司簡介
- AstraZeneca
- GlaxoSmithKline
- Merck Co. &Inc
- AbbVie Inc
- Clovis Oncology
- Medivation
- Johnson &Johnson Services, Inc
- Pfizer Inc.
- Genentech, Inc.
- Artios Pharma
- Repare Therapeutics Inc.
- Sierra Oncology, Inc.
- KaryopharmTherapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.

第10章分析師建議

命運之輪
分析師觀點
一致的機會圖

第11章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI3037

Global PARP inhibitor market is estimated to be valued at USD 7.20 Bn in 2024 and is expected to reach USD 13.02 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 7.20 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	8.80%	2031 Value Projection:	US$ 13.02 Bn

Figure. PARP Inhibitor Market Share (%), By Region 2024

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted therapies used mainly in cancer treatment. These work by blocking the action of PARP enzymes that repair damaged DNA, thus, helping chemotherapy and radiotherapy kill cancer cells more effectively. Global PARP inhibitor market growth is driven by rising cancer incidence, increasing approval and adoption of PARP inhibitors in oncology. Key drugs in the market include Olaparib, Niraparib and Rucaparib which have demonstrated efficacy in treating cancers like breast, ovarian and prostate. With ongoing research evaluating the potential of PARP inhibitors in newer cancer types and combination therapies, the can witness growth.

Market Dynamics:

Global PARP inhibitor market growth is primarily driven by increasing prevalence of cancer worldwide coupled with growing approval and adoption of PARP inhibitors in oncology. According to WHO, cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018. Continuous clinical trials evaluating the efficacy of PARP inhibitors in broader patient segments and combination with other anti-cancer therapies can drive the market growth. However, high cost of PARP inhibitors, requirement of genetic pre-screening for patient selection and imposition of stringent regulatory pathways for drug approval can hamper the market growth. Ongoing research exploring newer applications and emerging pipeline drugs can offer new opportunities for market growth in the near future.

Key Features of the Study:

This report provides in-depth analysis of the global PARP inhibitor market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global PARP inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca, Clovis Oncology, TESARO, AbbVie, Pfizer, Merck KGaA
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market

Detailed Segmentation-

By Drug Type
- Niraparib
- Olaparib
- Rucaparib
- Talazoparib
- Veliparib
- Others
By Application
- Ovarian Cancer
- Fallopian Tube Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- AstraZeneca
- GlaxoSmithKline
- Merck Co. & Inc
- AbbVie Inc
- Clovis Oncology
- Medivation
- Johnson & Johnson Services, Inc
- Pfizer Inc.
- Repare Therapeutics, Inc.
- Genentech, Inc.
- Artios Pharma
- Sierra Oncology, Inc.
- KaryopharmTherapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global PARP Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global PARP Inhibitor Market, By Drug Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Niraparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Olaparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Rucaparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Talazoparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Veliparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global PARP Inhibitor Market, By Application, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Ovarian Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Fallopian Tube Cancer
- Mammography
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Breast Cancer
- Chest X-ray
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Pancreatic Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global PARP Inhibitor Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global PARP Inhibitor Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- AstraZeneca
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GlaxoSmithKline
- Merck Co. & Inc
- AbbVie Inc
- Clovis Oncology
- Medivation
- Johnson & Johnson Services, Inc
- Pfizer Inc.
- Genentech, Inc.
- Artios Pharma
- Repare Therapeutics Inc.
- Sierra Oncology, Inc.
- KaryopharmTherapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.